The AHA Guidelines and Scientific Statements Handbook
The AHA Guidelines and Scientifi c Statements Handbook 8 An implantable cardioverter-defi brillator is rec- ommended as secondar ...
Chapter 13 Heart Failure with end-stage disease who cannot be stabilized with standard medical treatment (see recommendations fo ...
The AHA Guidelines and Scientifi c Statements Handbook 2 Routine intermittent infusions of positive inotro- pic agents are not r ...
Chapter 13 Heart Failure End-of-life considerations Recommendations Class I 1 Ongoing patient and family education regarding pro ...
At Risk for Heart Failure Heart Failure STAGE A At high risk for HF but without structural heart disease or symptoms of HF. e.g. ...
Chapter 13 Heart Failure Table 13.6 Heart Failure Guidelines across societies ESC ACC/AHA CCS HFSA Level Class Level Class Level ...
Cardiomyopathies Barry J. Maron 14 Introduction Defi nitions Classifi cation Primary cardiomyopathies Genetic Hypertrophic cardi ...
Chapter 14 Cardiomyopathies performance, which may be mechanical (e.g., dia- stolic or systolic dysfunction) or as a primary ele ...
The AHA Guidelines and Scientifi c Statements Handbook population for the disease phenotype recognized by echocardiography), and ...
Chapter 14 Cardiomyopathies incomplete penetrance. Dominant ARVC/D has been mapped to eight chromosomal loci, with muta- tions i ...
The AHA Guidelines and Scientifi c Statements Handbook short arm of chromosome 3, but no gene has yet been identifi ed. SUNDS, f ...
Chapter 14 Cardiomyopathies envelope intermediate fi lament protein. Mutations in this gene also cause Emery–Dreifuss muscular d ...
The AHA Guidelines and Scientifi c Statements Handbook Myocarditis typically evolves through active, healing and healed stages, ...
Chapter 14 Cardiomyopathies cation itself which ultimately separates disease states into familial and nonfamilial categories (ra ...
Atrial Fibrillation Valentin Fuster and Lars Rydén 15 Organization of committee and evidence Review Changes since the initial pu ...
Chapter 15 Atrial Fibrillation edition. Efforts were made to maintain consistency with other ACC/AHA and ESC practice guidelines ...
The AHA Guidelines and Scientifi c Statements Handbook 2 It is reasonable to use ablation of the AV node or accessory pathway to ...
Chapter 15 Atrial Fibrillation Fig. 15.3 Stroke rates in relation to age among patients in untreated control groups of randomize ...
The AHA Guidelines and Scientifi c Statements Handbook who are unable to safely tolerate anticoagulation at the standard intensi ...
Chapter 15 Atrial Fibrillation maximum target INR of 3.0 to 3.5. (Level of Evi- dence: C) Class III Long-term anticoagulation wi ...
«
8
9
10
11
12
13
14
15
16
17
»
Free download pdf
